Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Sarcoma, Myeloid 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 30Vincristine 22Rituximab 19Etoposide 19Prednisone 18Filgrastim 16Doxorubicin 16Cytarabine 16Methotrexate 15Radiotherapy 14Peripheral Blood Stem Cell Transplantation 13merphos 11Leucovorin 11blinatumomab 10N,N-dicyclohexyl-isoborneol-10-sulfonamide 10Mercaptopurine 10Dexamethasone 10azathiopurine 9Specimen Handling 9Methylprednisolone 9Calcium Dobesilate 9Biopsy 9dexamethasone acetate 8dexamethasone 21-phosphate 8auricularum 8Cyclosporine 8prednylidene 7pegaspargase 7fludarabine phosphate 7deltacortene 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Burkitt Lymphoma × Leyk × Clear all
NCT02101853 2026-06-03

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
669 enrolled 14 charts
Lymphoid

Burkitt Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡